What Caused Sarepta Therapeutics to Rally 12.6% in September

After reporting early-stage data from a drug candidate for the treatment of Duchenne muscular dystrophy (DMD) on September 6, shares in Sarepta Therapeutics (NASDAQ: SRPT) jumped 12.6% last month, according to S&P Global Market Intelligence.

DMD is a muscle-wasting disease that's caused by the inadequate production of dystrophin, a key protein necessary for building and maintaining muscle. DMD patients fail to produce enough dystrophin because of mutations at specific exons in the dystrophin production sequence, and as a result, most patients fail to live beyond their 30s.

IMAGE SOURCE: GETTY IMAGES.

Source: Fool.com